Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249366 · ClinicalTrials.gov registry record · Phase 4
Treatment of Alcohol Withdrawal in Hospital Patients
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 4
- Development phase
- 183
- Enrollment target
NCT00249366 is a Phase 4 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 183 participants.
The verdict
NCT00249366, a Phase 4 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 183 participants
- Enrollment target
Study Summary
The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.
Interventions
- DRUG Lorazepam
- DRUG Lorazepam (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2001-04 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249366
The ClinicalTrials.gov registry entry for NCT00249366 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lorazepam is the first listed.
NCT00249366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249366 about?
NCT00249366 is a clinical study titled "Treatment of Alcohol Withdrawal in Hospital Patients". The purpose of this study is to test how tolerable and effective lorazepam is when used to treat alcohol withdrawal in hospital patients at risk for alcohol withdrawal.
What is the current status of trial NCT00249366?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 183 participants. The study started on 2001-04. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00249366?
The interventions under investigation include: Lorazepam (DRUG), Lorazepam (drug) (DRUG).
Who is sponsoring clinical trial NCT00249366?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.